338P - Association of kynurenine, tryptophan and key enzymes involved in kynurenine pathway of tryptophan catabolism with Imatinib duration in patients wi...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Leukaemia
Translational Research
Presenter Dheeraj Mohania
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors D. Mohania1, Y. Shokeen2, M. Jauhri2, S. Aggarwal2
  • 1Research, Sir Ganga Ram Hospital, 110060 - Delhi/IN
  • 2Medical Oncology, Sir Ganga Ram Hospital, 110060 - Delhi/IN

Abstract

Background

The kynurenine pathway could be a strong candidate for the missing link of immunosuppressive microenvironment in CML which has been demonstrated in a number of malignancies but not yet in CML patients.

Methods

Patients were classified into three groups (responders, resistant and treatment naïve) depending on their response to Imatinib (IM) therapy. The concentrations of the Trp and Kyn were measured by ELISA in the sera of 29 patients with CML and 19 healthy controls. We also investigated the expression of various key enzymes involved in kynurenine pathway for the first time in CML patients.

Results

Trp concentrations were significantly lower in patients with CML (treatment responders, resistant and naïve) than in healthy controls (p 

Conclusions

The present study gives an important evidence for the first time about the association of key enzymes involved in tryptophan catabolism with Imatinib duration in treatment responsive, resistant and treatment naïve CML patients. The prognostic power and relevance of this novel information remains to be elucidated in further larger studies.

Clinical trial indentification

Legal entity responsible for the study

Sir Ganga Ram Hospital, New Delhi, India

Funding

Department of Research, Sir Ganga Ram Hospital, New Delhi, India

Disclosure

All authors have declared no conflicts of interest.